Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.
Stock is 
Press Release
 View printer-friendly version << Back

Agios Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference

Cambridge, Mass. – January 3, 2011 – Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, today announced that David Schenkein, M.D., chief executive officer, is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2012 at 11:30 AM PST at the Westin St. Francis Hotel in San Francisco.

Dr. Schenkein is expected to discuss the company’s portfolio of cancer metabolism therapeutics, its expansion into targeting inborn errors of metabolism, and the assets and capabilities that position Agios as a leader in dysregulated metabolism.

About Agios Pharmaceuticals

Agios Pharmaceuticals is the first biopharmaceutical company dedicated to the discovery and development of novel therapeutics in the field of cancer metabolism. To support and drive these efforts, Agios has built a robust platform integrating cancer biology, metabolomics, biochemistry and informatics to enable target and biomarker identification. Agios’ capabilities to interrogate differential cellular metabolism of diseased cells relative to normal cells may also be applicable to other therapeutics areas including inborn errors of metabolism, a class of genetic diseases caused by mutations/defects of single metabolic genes. The company’s founders represent the core thought leaders in the field of cancer metabolism, responsible for key advances, insights and discoveries in the field. Agios Pharmaceuticals is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.agios.com.